Trial of Parkinson's And Zoledronic Acid (TOPAZ)
Project Summary: This study is a randomized placebo-controlled trial of a single infusion of zoledronic acid-5 mg for the prevention of fractures in 3500 men and women aged 65 years and older with Parkinson’s disease willing and able to continue in follow-up for up to 5 years.
PI(s):Steven Cummings, MD
PaTH Protocol PI(s):
- Susan Greenspan, MD – University of Pittsburgh
- Mihai Sandulescu, MD – Geisinger Health System
Purpose: To test the efficacy of Zoledronic acid compared with placebo to reduce the risk of clinical fractures in Parkinson’s disease patients.
Goal(s): To reduce clinical fractures in Parkinson’s disease patients. Study Design: This is a multi-center, site-less clinical trial that will utilize telemedicine and nurse home visits to interact with participants.
PaTH Partners:
- The University of Pittsburgh
- Geisinger Health System
Sponsor: NIA/NIH
Coordinating Center: San Francisco Coordinating Center How to Participate: Participants interested in joining the study can visit topazstudy.org to complete the electronic informed consent and a health survey.
